simvastatin has been researched along with Germinoblastoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, K; Kambayashi, S; Kobayashi, K; Okuda, M | 1 |
| Cai, DQ; Kim, CS; Kim, DH; Kim, SK; Lee, KJ; Qi, XF; Qin, JW; Wu, Z; Yu, YH; Zheng, L | 1 |
| Cohen, JI; Katano, H; Pesnicak, L | 1 |
| Cohen, JI | 1 |
| Aoyama, T; Hara, S; Iwata, H; Kami, M; Kanda, Y; Matsuo, K; Mori, S; Murashige, N; Mutou, Y; Odawara, M; Suzuki, R; Tachibana, S; Takeuchi, K; Yamane, M | 1 |
| Bloem, AC; Bogers, LH; de Weerdt, O; Kramer, MH; Lokhorst, HM; van de Donk, NW; van der Griend, R; van der Spek, E; Wittebol, S | 1 |
1 review(s) available for simvastatin and Germinoblastoma
| Article | Year |
|---|---|
HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.
Topics: Animals; Cell Transformation, Viral; Enzyme Inhibitors; Herpesvirus 4, Human; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphoma; Mice; Simvastatin | 2005 |
1 trial(s) available for simvastatin and Germinoblastoma
| Article | Year |
|---|---|
Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma; Maximum Tolerated Dose; Multiple Myeloma; Recurrence; Salvage Therapy; Simvastatin; Treatment Outcome | 2006 |
4 other study(ies) available for simvastatin and Germinoblastoma
| Article | Year |
|---|---|
Effect of simvastatin on cell proliferation and Ras activation in canine tumour cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dog Diseases; Dogs; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphoma; Melanoma; ras Proteins; Simvastatin | 2021 |
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Topics: Acetylcysteine; Acyl Coenzyme A; Animals; Antioxidants; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; DNA Fragmentation; Extracellular Signal-Regulated MAP Kinases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lymphoma; Membrane Potential, Mitochondrial; Mevalonic Acid; Mice; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reactive Oxygen Species; Signal Transduction; Simvastatin | 2013 |
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.
Topics: Animals; Apoptosis; Cell Line, Transformed; Cell Transformation, Viral; Humans; Lymphoma; Mice; Mice, SCID; NF-kappa B; Simvastatin; Viral Matrix Proteins | 2004 |
Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Japan; Lymphoma; Male; Multiple Myeloma; Pravastatin; Risk Factors; Simvastatin | 2006 |